284 related articles for article (PubMed ID: 6214986)
1. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
Brown JE; Del Bene VE; Collins CD
Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
[TBL] [Abstract][Full Text] [Related]
2. Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa.
Corrado ML; Landesman SH; Cherubin CE
Antimicrob Agents Chemother; 1980 Dec; 18(6):893-6. PubMed ID: 6263178
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp.
Nasu M; Maskell JP; Williams RJ; Williams JD
Antimicrob Agents Chemother; 1981 Oct; 20(4):433-6. PubMed ID: 6282191
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
Owens WE; Finegold SM
Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
[TBL] [Abstract][Full Text] [Related]
5. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
Hanslo D; King A; Shannon K; Warren C; Phillips I
J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
[No Abstract] [Full Text] [Related]
6. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.
Verbist L; Verhaegen J
Antimicrob Agents Chemother; 1981 Mar; 19(3):402-6. PubMed ID: 6264844
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
Pusztai-Markos Z; Pranada F
Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of cefbuperazone compared with that of other new beta-lactam agents against anaerobic gram-negative bacilli and contribution of beta-lactamase to resistance.
Del Bene VE; Carek PJ; Twitty JA; Burkey LJ
Antimicrob Agents Chemother; 1985 May; 27(5):817-20. PubMed ID: 3874597
[TBL] [Abstract][Full Text] [Related]
9. In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.
Cynamon MH; Granato PA
Chemotherapy; 1982; 28(3):204-8. PubMed ID: 6212205
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins.
Cynamon MH; Palmer GS
Antimicrob Agents Chemother; 1982 Dec; 22(6):1079-81. PubMed ID: 6961887
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of N-formimidoyl thienamycin with third generation cephalosporins and ureido penicillins against multiple resistant Serratia marcescens.
Miller MA; LeFrock JL; Vercler MJ
Microbiol Immunol; 1981; 25(11):1119-27. PubMed ID: 6276701
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.
Cullmann W; Opferkuch W; Stieglitz M; Werkmeister U
Antimicrob Agents Chemother; 1982 Aug; 22(2):302-7. PubMed ID: 6821459
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of intestinal anaerobes to new beta-lactam antibiotics.
Bansal MB; Chuah SK; Thadepalli H
Chemotherapy; 1984; 30(4):237-43. PubMed ID: 6744975
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria.
Rolfe RD; Finegold SM
Antimicrob Agents Chemother; 1981 Nov; 20(5):600-9. PubMed ID: 7325628
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production.
Aldridge KE; Sanders CV; Lewis AC; Marier RL
J Med Microbiol; 1983 Feb; 16(1):75-82. PubMed ID: 6218305
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
Braveny I; Machka K; Elsser R
Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
[TBL] [Abstract][Full Text] [Related]
17. In-vitro antagonism by N-formimidoyl thienamycin and cefoxitin of second and third generation cephalosporins in Aeromonas hydrophila and Serratia marcescens.
Miller MA; Finan M; Yousuf M
J Antimicrob Chemother; 1983 Apr; 11(4):311-8. PubMed ID: 6343337
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
Hoellman DB; Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Mar; 42(3):495-501. PubMed ID: 9517922
[TBL] [Abstract][Full Text] [Related]
19. N-formimidoyl thienamycin: in vitro comparison with cefoxitin and tobramycin against clinical, bacterial isolates.
Digranes A; Dibb WL; Benonisen E
Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):141-4. PubMed ID: 6603093
[TBL] [Abstract][Full Text] [Related]
20. Cefoperazone against carbenicillin-resistant isolates of Pseudomonas aeruginosa: comparison with other newer cephalosporins and N-formimidoyl thienamycin.
Chau PY; Ling J; Ng WS
J Antimicrob Chemother; 1983 Oct; 12(4):337-45. PubMed ID: 6417100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
